We have an uncommon migraine treatment for you today!
Click here and scroll down for previous newsletters.
1. Pictured Counselling Cue Card: a free sample of our counselling reference
2. Patient Consultation: exactly what a pharmacist may say to a patient picking up this medication, with formatting to show where the information is coming from on the cue card
Clearly, there are nuances that may not be captured in this format. The goal here is to provide you with an example of how a pharmacist may counsel a patient. Basic counselling tactics (e.g. showing the patient the labeled medication as you read it, having the patient repeat the information in their own words, double checking allergies, and so on) may not be depicted in the interest of keeping the content concise.
RPh: Hi! Is this medication new for you?
Patient: Yes.
RPh: Ok. What has (prescriber) told you?
Patient: They said it would help with my migraines. I had previously been taking Imitrex and it wasn't working.
RPh: Ok. This medication is called UBROGEPANT, also known as UBRELVY, and you'll take it (as directed). It's in the family of what's called CGRPr blockers, but basically it will help quickly treat your migraine. It works differently than Imitrex, but you can also repeat a dose in 2 h if you find your migraine is still lingering. You can take it with or without food, however, avoid food if your migraines make you nauseous and also avoid fatty foods as it can make the medication work slower. It's generally well-tolerated, but some side effects may include nausea, drowsiness, and dry mouth; please let us or your (prescriber) know if these become bothersome. This medication may not be right for you if you have severe kidney disease, or if you are taking certain prescription medications or St. John's Wort. Keep it at room temperature.
RPh: Did you have any questions?
Patient: Is this safe if I have liver problems?
RPh: The dose may need to be reduced if your liver is not working properly. I will look into that for you.
Patient: Ok, thank you.
We hope you have found this useful, and please reply to this email with any feedback or topic suggestions you can. It will be the key to making this newsletter the best it can be.
Comments